National Lipid Association Issues New Recommendations For Patient-Centered Management Of Cholesterol

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 15, 2014 /PRNewswire/ -- Today, the National Lipid Association (NLA) released new recommendations based on a panel of independent experts, published in the Journal of Clinical Lipidology. The recommendations highlight the importance of doctors and patients setting cholesterol goals and focusing on patient’s risk and risk factors, rather than on specific categories of medication. The recommendations take into account that each patient’s unique medical and personal history requires a multifaceted approach to prevention and treatment; and that a strong patient-provider relationship is essential to achieve long-term success in preventing cardiovascular disease.

National Lipid Association

“The new NLA recommendations are targeted at healthcare providers to help patients better understand their treatment options, reduce cardiovascular risk, and set actionable and attainable goals for treatment,” said Dr. Terry A. Jacobson, MD, President, National Lipid Association, and Professor of Medicine, Emory University. “The panel emphasizes that patients and providers working in partnership to achieve mutually agreed-upon cholesterol and lifestyle goals will equip patients with the metrics of success needed to prevent and reduce cardiovascular events.”

The new recommendations can guide healthcare providers in the diagnosis and treatment of lipid disorders. They are intended to provide additional expert guidance to previous guidelines currently available for the treatment of blood cholesterol.

The NLA expert panel’s consensus emphasizes that a more comprehensive measure of cholesterol-related risk called non-high-density lipoprotein cholesterol (non-HDL-C) is a better primary target for treatment than the traditionally reported LDL-C, which is commonly referred to as the “bad cholesterol.” The Non-HDL cholesterol is simply the difference between the total cholesterol concentration and the HDL, or “good cholesterol,” and can be obtained in the non-fasting state without additional cost.

For the main conclusions of the NLA Recommendations for Patient-Centered Management of Dyslipidemia, see lipid.org/recommendations/conclusions.

Many approaches that safely lower blood cholesterolincluding improved dietary and exercise habits and several medicationshave been shown to reduce cardiovascular risk in higher-risk individuals. While statin medications in specific doses have the most supportive evidence, clinical judgment should be used to determine the best individual approach for each patient.

About the National Lipid Association
The NLA is a multidisciplinary specialty society focused on prevention of cardiovascular disease and other lipid-related disorders. The NLA’s mission is to enhance the practice of lipid management in clinical medicine, and one of their goals is to enhance efforts to reduce death and disability related to disorders of lipid metabolism in patients. Members include physicians (MDs and DOs), as well as allied health clinical team members, including PhD researchers, nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians.

Contact:
Ravi Sunnak
Havas PR North America
+1-917-412-4473
ravi.sunnak@havasww.com

Logo - http://photos.prnewswire.com/prnh/20140915/146053

SOURCE National Lipid Association

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC